ET BureauThe Subject Expert Committee (SEC) under the Central Drugs Control Standard Organisation on Friday recommended Serum Institute of India's (SII) Covid-19 vaccine, Covovax, for emergency use authorisation in the 12-17 age group, people in the know told ET.
The recommendation is yet to be approved by the DCGI. Pune-based SII had last month sought restricted emergency use of Covovax in adolescents.
The WHO in December last year allowed emergency use of SII's version of US firm Novavax's Covid-19 vaccine. As of now, only Bharat Biotech's Covaxin is being used to vaccine those in the age group between 15 and 18.
Earlier in February, the DCGI granted approval to Biological E's Corbevax for use in adolescents aged between 12 and 18. However, this vaccine is yet to be included in the vaccination drive. According to the health ministry on Friday, India has administered more than 1.78 billion Covid-19 vaccine doses. In the last 24 hours, 2.48 million vaccine doses were administered.
The recommendation is yet to be approved by the DCGI. Pune-based SII had last month sought restricted emergency use of Covovax in adolescents.
The WHO in December last year allowed emergency use of SII's version of US firm Novavax's Covid-19 vaccine. As of now, only Bharat Biotech's Covaxin is being used to vaccine those in the age group between 15 and 18.
Earlier in February, the DCGI granted approval to Biological E's Corbevax for use in adolescents aged between 12 and 18. However, this vaccine is yet to be included in the vaccination drive. According to the health ministry on Friday, India has administered more than 1.78 billion Covid-19 vaccine doses. In the last 24 hours, 2.48 million vaccine doses were administered.
Read More News on
(Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
